GTXI vs. LXRX, AGEN, XOMA, VNDA, EBS, CDXS, ACHV, RIGL, RGLS, and SGMO
Should you be buying GTX stock or one of its competitors? The main competitors of GTX include Lexicon Pharmaceuticals (LXRX), Agenus (AGEN), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Codexis (CDXS), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), and Sangamo Therapeutics (SGMO). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and GTX (NASDAQ:GTXI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking.
GTX has lower revenue, but higher earnings than Lexicon Pharmaceuticals. GTX is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Lexicon Pharmaceuticals received 150 more outperform votes than GTX when rated by MarketBeat users. However, 73.60% of users gave GTX an outperform vote while only 64.58% of users gave Lexicon Pharmaceuticals an outperform vote.
Lexicon Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, GTX has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.
GTX has a net margin of 0.00% compared to GTX's net margin of -8,311.12%. Lexicon Pharmaceuticals' return on equity of -104.19% beat GTX's return on equity.
74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of GTX shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 40.9% of GTX shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 4 articles in the media. GTX's average media sentiment score of 0.47 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.
Lexicon Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 194.12%. Given GTX's higher possible upside, equities analysts clearly believe Lexicon Pharmaceuticals is more favorable than GTX.
Summary
Lexicon Pharmaceuticals beats GTX on 9 of the 15 factors compared between the two stocks.
Get GTX News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
